S&P Futures
3,846.50 -1.75 (-0.05%) Dow Futures
30,997.00 -16.00 (-0.05%) Nasdaq Futures
11,882.50 +2.25 (+0.02%) Russell 2000 Futures
1,728.60 0.00 (0.00%) Crude Oil
97.63 -0.90 (-0.91%) Gold
1,738.00 +1.50 (+0.09%)
Aptevo Therapeutics Inc. (APVO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.7700 |
| Open | 3.8800 |
| Bid | 3.8000 x 900 |
| Ask | 3.9100 x 1300 |
| Day's Range | 3.8000 - 4.1500 |
| 52 Week Range | 3.0300 - 22.5000 |
| Volume | |
| Avg. Volume | 97,375 |
| Market Cap | 19.528M |
| Beta (5Y Monthly) | 6.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.9980 |
| Earnings Date | May 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for APVO
Related Research
- Aptevo Therapeutics Inc.Technical Assessment: Bearish in the Intermediate-TermCommodities continue to get shellacked, Treasury yields across the curve are still falling, people are starting to suggest that the Federal Reserve won't have to tighten as much as many thought just a month or two ago, recession fears (or worries that we are already in one) are rising quickly, EPS season is almost upon us (with many believing 2022 numbers are far too high), crypto remains in the dumpster, and the horrendous invasion of Ukraine never ends.RatingFair ValueEconomic Moat19 hours agoArgus Research
- ACCESSWIRE
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to DateCohort 3 Monotherapy Patient Achieved Bone Marrow Complete RemissionCompany Also Reports Myelodysplastic Syndrome Patient Enrolled in Dose Escalation Trial Remains Stable and on APVO436 After 18 Months of TreatmentSEATTLE, WA / ACCESSWIRE / June 9, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel im
- ACCESSWIRE
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results and business highlights for the quarter ended March 31, 2022.
- ACCESSWIRE
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant DiseaseSEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the presentation of preclinical data for APVO442 in a poster session at the American
